Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development

July 28, 2023

Sirnaomics is a clinical-stage RNA therapeutics biopharmaceutical company developing STP705 for non-melanoma skin cancer, among other therapeutics.

Dr. Francois Lebel, M.D is the new Senior Vice President for preclinical and clinical development at Sirnaomics Ltd.

"With multiple drug candidates moving into clinical studies, including two clinical trials advancing to late-stage development, Sirnaomics is embarking on a journey to push its innovative drug candidates past the finish line, which requires a seasoned leader with a successful track record," says Dr. Patrick Lu, Founder, Chairman of the Board, Executive Director, President and Chief Executive Officer of Sirnaomics, in a news release. 

"With Dr. Lebel's in-depth knowledge and experience in novel drug product marketing approvals, Dr. Lebel's addition to Sirnaomics' senior leadership will greatly enhance our capability to advance its therapeutic candidates through the late-stage product development.”

Throughout his 30-year biopharma career at companies such as GSK, Pfizer, Baxter Healthcare, Medlmmune, and Chiron Corporation, Dr. Lebel has designed and managed international research and development programs to achieve multiple product marketing approvals. His recent senior leadership roles include Executive Vice President for Research & Development and Chief Medical Officer at Spectrum Pharmaceuticals, where he was responsible for preclinical and clinical development, regulatory affairs and pharmacovigilance/drug safety, and secured a novel drug marketing authorization at the U.S. Food and Drug Administration (FDA) in 2022. After joining Sirnaomics as Senior Vice President for preclinical and clinical development, Dr. Lebel will take a leading role in the Group's late-stage product development of the innovative RNAi drug candidates.

"I am delighted to join the Sirnaomics team at this pivotal time for STP705 with the recent positive data in skin cancer and the Group's evolving diversified pipeline,” says  Dr. Lebel. “I look forward to working closely with the U.S. FDA and investigators to efficiently generate the required data to support a marketing application."

Facebook Comments

Register

We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free